Based on today's economic data, you would certainly have expected a more robust rally than what the broad-based S&P 500 (INDEXSP:.INX) ended up gaining, but beggars can't be...
Keep Reading →
September 4 - News
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
August 27 - News
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Keep Reading →
August 26 - News
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
At some point, a company reaches a level of maximum valuation. It doesn't mean the company becomes bad, but rather all upside is priced in and future gains are limited.
Keep Reading →
August 22 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection.
Keep Reading →
August 12 - News
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.
Keep Reading →
August 12 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates.
Keep Reading →
August 9 - News
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Keep Reading →
August 8 - News
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug.
Keep Reading →
August 8 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 7 - News
Around four in 10 Americans live in places where smog can impact their health.
Keep Reading →
August 5 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will release its quarterly report on Tuesday, and the company's stock has been on an absolute tear over the past year.
Keep Reading →
August 2 - News
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company ...
Keep Reading →
July 19 - News
In today’s information age, people like to be active, and follow their investments closely.
Keep Reading →
July 15 - News
On Friday we saw several stock-moving upgrades in preparation of a long week of earnings; here are four that really caught my eye.
Keep Reading →
July 13 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
July 3 - News
In April of last year I decided that the boundaries of financial metrics no longer mattered to me, and I embarked on creating my own unique index, dubbed the TMFULOI, to examine...
Keep Reading →
July 3 - News
The entire biotech space is moving higher in response to the bid for Onyx Pharmaceuticals, especially those with Orphan blockbusters.
Keep Reading →
July 2 - News
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Keep Reading →
June 27 - News
Earnings per share, or EPS, shows the rate at which a company has grown its profitability. EPS growth is a good fundamental indicator of the future prospects of a company.
Keep Reading →
June 27 - News
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) got crushed with a downgrade from Credit Suisse that led to a 6.3% loss on Monday.
Keep Reading →
June 25 - News
Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche's vaccine market share.
Keep Reading →
June 21 - News
Anticipation of tomorrow's Federal Reserve open market meeting is building, and the indication from investors thus far, following a second straight day of big gains in the broad...
Keep Reading →
June 19 - News
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Keep Reading →
June 18 - News
Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions.
Keep Reading →
June 18 - News
Biotechnology's a volatile sector that can intimidate many investors, but it's also a landscape of stocks that can reward portfolios with giant gains.
Keep Reading →
June 17 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher.
Keep Reading →
June 17 - News
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry...
Keep Reading →
June 13 - News
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
Keep Reading →
June 12 - News
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic.
Keep Reading →
June 12 - News
It hasn't happened nearly as often as optimists would like to see in recent weeks, but improving economic data matched the move higher in the broad-based S&P 500 today, and gave...
Keep Reading →
June 7 - News
To the average investor, there are dozens of indicators market participants can use to analyze the equity markets.
Keep Reading →
June 3 - News
For many companies, rising to become part of the S&P 500 (S&P Indices:.INX) represents the pinnacle of their achievement.
Keep Reading →
June 3 - News
Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 31 - News
Some stocks seem to have all the luck, offering the best of both worlds.
Keep Reading →
May 30 - News
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Keep Reading →
May 24 - News
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Keep Reading →
May 23 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260.
Keep Reading →
May 23 - News
Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer (as a first-line and second-line treatment), metastatic HER2-negative breast...
Keep Reading →
May 19 - News
Editor's Note: Related Tickers: First Solar, Inc.
Keep Reading →
May 13 - News
On March 28, more than three weeks after the Dow Jones Industrial Average (Dow Jones Indices:.DJI) managed to climb to a new all-time record high, the S&P 500 finally followed...
Keep Reading →
May 12 - News
Investments in biotechnology by the average investor tend to deliver hit or miss returns over time.
Keep Reading →
May 8 - News
